Regulatory T-cell therapy for transplantation: How many cells do we need?

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 349-354

  Tang, Qizhi ^a   Lee, Karim ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

regulatory T cells; T cell immunotherapy; transplant tolerance

Indexed keywords

ALLOANTIGEN; INTERLEUKIN 2; THYMOCYTE ANTIBODY;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL ISOLATION; CELL LINEAGE; CELL THERAPY; DENDRITIC CELL; GRAFT REJECTION; HUMAN; IN VITRO STUDY; LYMPH NODE; LYMPHOID TISSUE; MIXED LYMPHOCYTE REACTION; NONHUMAN; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION;

ANIMALS; GRAFT REJECTION; HUMANS; LYMPHOCYTE COUNT; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TISSUE THERAPY;

EID: 84863840517     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355a992     Document Type: Review

References (59)

1. Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4-CD25-CD127-T regulatory cells. Clin Immunol 2009; 133:22-26.
2. Brunstein CG, Miller JS, CaoQ, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2010; 117:1061-1070.
3. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
4. Leslie M. Immunology. Regulatory T cells get their chance to shine. Science 2011; 332:1020-1021.
5. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007; 7:650-654.
6. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7:585-598.
7. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant 2008; 13:645-653.
8. Waldmann H, Adams E, Fairchild P, Cobbold S. Regulation and privilege in transplantation tolerance. J Clin Immunol 2008; 28:716-725.
9. Long E, Wood KJ. Regulatory T cells in transplantation: transferring mouse studies to the clinic. Transplantation 2009; 88:1050-1056.
10. Tang Q, Bluestone JA, Kang SM. CD4-Foxp3-regulatory T cell therapy in transplantation. J Mol Cell Biol 2011; 4:11-21.
11. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166:3789-3796.
12. Graca L, Thompson S, Lin CY, et al. Both CD4-CD25-and CD4-CD25-regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168:5558-5565.
13. Fan Z, Spencer JA, Lu Y, et al. In vivo tracking of color-coded effector, natural and induced regulatory T cells in the allograft response. Nat Med 2010; 16:718-722.
14. Francis RS, Feng G, Tha-In T, et al. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol 2011; 41:726-738.
15. Kendal AR, Chen Y, Regateiro FS, et al. Sustained suppression by Foxp3-regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208:2043-2053.
16. Ganusov VV, De Boer RJ. Do most lymphocytes in humans really reside in the gut? Trends Immunol 2007; 28:514-518.
17. Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr 1974; 52:511-515.
18. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108: 45-51.
19. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992; 70:539-544.
20. Fujimaki W, Takahashi N, Ohnuma K, et al. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol 2008; 305859.
21. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949.
22. Nylen S, Maurya R, Eidsmo L, et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4-CD25-(Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204:805-817.
23. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4-CD25-regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64:8451-8455.
24. Hartl D, Koller B, Mehlhorn AT, et al. Quantitative and functional impairment of pulmonary CD4-CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007; 119:1258-1266.
25. Oo YH, Weston CJ, Lalor PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010; 184:2886-2898.
26. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3-CD4-regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007; 13:191-199.
27. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4-CD25-thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001; 31:1247-1254.
28. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71:460-468.
29. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for antithymocyte globulin: induction of CD4-CD25-Foxp3-regulatory T cells. J Am Soc Nephrol 2006; 17:2844-2853.
30. Morelon E, Lefrancois N, Besson C, et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol 2010; 23:53-58.
31. Hoffmann P, Boeld TJ, Eder R, et al. Loss of FOXP3 expression in natural human CD4-CD25-regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009; 39:1088-1097.
32. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58:652-662.
33. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4-CD25-regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112: 1688-1696.
34. Golshayan D, Jiang S, Tsang J, et al. In vitro-expanded donor alloantigenspecific CD4-CD25-regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109:827-835.
35. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4-CD25-Foxp3-regulatory T lymphocytes. Nat Med 2008; 14:88-92.
36. Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect allospecificity on CD4-CD25-Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118:3619-3628.
37. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
38. Brennan TV, Tang Q, Liu FC, et al. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. J Surg Res 2011; 169:e69-e75.
39. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3:83ra42.
40. Peters JH, Hilbrands LB, Koenen HJ, Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS One 2008; 3:e2233.
41. Chen LC, Delgado JC, Jensen PE, Chen X. Direct expansion of human allospecific FoxP3-CD4-regulatory T cells with allogeneic B cells for therapeutic application. J Immunol 2009; 183:4094-4102.
42. Veerapathran A, Pidala J, Beato F, et al. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood 2011; 118:5671-5680.
43. Lin YJ, Hara H, Tai HC, et al. Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses. Transplantation 2008; 86:1452-1462.
44. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188:1641-1650.
45. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998; 8:413-416.
46. Tran GT, Hodgkinson SJ, Carter NM. IL-5 promotes induction of antigen specific CD4-CD25-T regulatory cells that suppress autoimmunity. Blood 2012; 119:4441-4450.
47. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25-CD4-regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198:235-247.
48. Yamazaki S, Patel M, Harper A, et al. Effective expansion of alloantigenspecific Foxp3-CD25-CD4-regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A 2006; 103:2758-2763.
49. Tonomura N, Habiro K, Shimizu A, et al. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood 2008; 111:4293-4296.
50. Peters JH, Preijers FW, Woestenenk R, et al. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One 2008; 3:e3161.
51. Chen Q, Kim YC, Laurence A, et al. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3-T cells in vivo. J Immunol 2011; 186:6329-6337.
52. Daniel C, Wennhold K, Kim HJ, von Boehmer H. Enhancement of antigenspecific Treg vaccination in vivo. Proc Natl Acad Sci U S A 2010; 107: 16246-16251.
53. van Loosdregt J, Brunen D, Fleskens V, et al. Rapid temporal control of Foxp3 protein degradation by sirtuin-1. PLoS One 2011; 6:e19047.
54. de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3-T-regulatory cells. Mol Cell Biol 2011; 31:2066-2078.
55. Kwon HS, Lim HW, Wu J, et al. Three novel acetylation sites in the foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol 2012; 188:2712-2721.
56. Feng G, Nadig SN, Backdahl L, et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med 2011; 3:83ra40.
57. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-1476.
58. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887-1895.
59. Selin LK, Brehm MA, Naumov YN, et al. Memory of mice and men: CD8-T-cell cross-reactivity and heterologous immunity. Immunol Rev 2006; 211: 164-181.